Climb Bio, Inc. (NASDAQ:CLYM) Receives $9.00 Average Price Target from Analysts

Shares of Climb Bio, Inc. (NASDAQ:CLYM) have been assigned an average recommendation of “Buy” from the six analysts that are covering the company, MarketBeat Ratings reports. Four analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $9.00.

Several equities research analysts recently commented on CLYM shares. Robert W. Baird started coverage on shares of Climb Bio in a research report on Friday, August 15th. They set an “outperform” rating and a $9.00 target price on the stock. BTIG Research started coverage on shares of Climb Bio in a research report on Thursday, May 22nd. They set a “buy” rating on the stock. Oppenheimer initiated coverage on shares of Climb Bio in a research report on Friday, June 6th. They set an “outperform” rating and a $10.00 target price on the stock. Finally, Baird R W upgraded shares of Climb Bio to a “strong-buy” rating in a report on Friday, August 15th.

Climb Bio Price Performance

NASDAQ:CLYM opened at $2.40 on Tuesday. The firm’s 50 day simple moving average is $1.81 and its 200 day simple moving average is $1.46. Climb Bio has a one year low of $1.05 and a one year high of $8.79. The company has a market cap of $162.62 million, a PE ratio of -3.43 and a beta of -0.05.

Climb Bio (NASDAQ:CLYM) last posted its earnings results on Tuesday, August 12th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.19) by $0.06. Equities research analysts expect that Climb Bio will post -1.57 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in CLYM. Bank of New York Mellon Corp bought a new position in Climb Bio during the 1st quarter worth approximately $79,000. Peapod Lane Capital LLC bought a new position in Climb Bio during the 1st quarter worth approximately $676,000. TD Asset Management Inc bought a new stake in shares of Climb Bio in the 1st quarter valued at $109,000. XTX Topco Ltd bought a new stake in shares of Climb Bio in the 1st quarter valued at $34,000. Finally, Charles Schwab Investment Management Inc. bought a new stake in shares of Climb Bio in the 1st quarter valued at $86,000. Institutional investors own 69.76% of the company’s stock.

Climb Bio Company Profile

Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases.